Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab

Ann Oncol. 2017 Aug 1;28(8):2040-2041. doi: 10.1093/annonc/mdx233.

Authors

A Curioni-Fontecedro¹, C Ickenberg², D Franzen³, G Rogler⁴, I A Burger⁵, M van den Broek⁶

Affiliations

¹ Department for Hematology and Oncology, Division of Oncology.
² Institute of Pathology and Molecular Pathology.
³ Division of Pulmonology.
⁴ Departments of Gastroenterology and Hepatology.
⁵ Nuclear Medicine, University Hospital Zurich, Zurich.
⁶ Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

PMID: 28838208
DOI: 10.1093/annonc/mdx233

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Disease Progression
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Nivolumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Nivolumab